keyword
https://read.qxmd.com/read/38565249/a-germline-point-mutation-in-the-myc-fbw7-phosphodegron-initiates-hematopoietic-malignancies
#21
JOURNAL ARTICLE
Brian Freie, Patrick A Carroll, Barbara J Varnum-Finney, Erin L Ramsey, Vijay Ramani, Irwin Bernstein, Robert N Eisenman
Oncogenic activation of MYC in cancers predominantly involves increased transcription rather than coding region mutations. However, MYC-dependent lymphomas frequently acquire point mutations in the MYC phosphodegron, including at threonine 58 (T58), where phosphorylation permits binding via the FBW7 ubiquitin ligase triggering MYC degradation. To understand how T58 phosphorylation functions in normal cell physiology, we introduced an alanine mutation at T58 (T58A) into the endogenous c-Myc locus in the mouse germline...
April 2, 2024: Genes & Development
https://read.qxmd.com/read/38558131/targeting-metabolic-dependencies-fueling-the-tca-cycle-to-circumvent-therapy-resistance-in-acute-myeloid-leukemia
#22
JOURNAL ARTICLE
Emeline Boët, Jean-Emmanuel Sarry
Acute myeloid leukemia (AML) is one of the most prevalent blood cancers, characterized by a dismal survival rate. This poor outcome is largely attributed to AML cells that persist despite treatment and eventually result in relapse. Relapse-initiating cells exhibit diverse resistance mechanisms, encompassing genetic factors and, more recently discovered, nongenetic factors such as metabolic adaptations. Leukemic stem cells (LSC) rely on mitochondrial metabolism for their survival, whereas hematopoietic stem cells primarily depend on glycolysis...
April 1, 2024: Cancer Research
https://read.qxmd.com/read/38545694/internal-m-6-a-and-m-7-g-rna-modifications-in-hematopoietic-system-and-acute-myeloid-leukemia
#23
JOURNAL ARTICLE
Xiaoxu Zhang, Yanni Ma, Jia Yu, Rui Su, Xiaoshuang Wang
Epitranscriptomics focuses on RNA modifications-mediated post-transcriptional regulation of gene expression. The current decade has witnessed tremendous progress in understanding the landscapes and biological functions of RNA modifications as prompted by potent analytical approaches. The hematopoietic system provides a lifelong supply of blood cells, and gene expression is tightly modulated during the differentiation of hematopoietic stem cells (HSCs). Dysregulation of gene expression during hematopoiesis may lead to severe disorders, including acute myeloid leukemia (AML)...
March 28, 2024: Chinese Medical Journal
https://read.qxmd.com/read/38544839/unraveling-trajectories-from-aplastic-anemia-to-hematologic-malignancies-genetic-and-molecular-insights
#24
JOURNAL ARTICLE
Namsoo Kim, Yu Jeong Choi, Seung-Tae Lee, Jong Rak Choi, Chuhl Joo Lyu, Saeam Shin, June-Won Cheong
BACKGROUND: Aplastic anemia (AA), characterized by hematopoietic stem cell deficiency, can evolve into different hematologic malignancies. Our understanding of the genetic basis and mechanisms of this progression remains limited. METHODS: We retrospectively studied 9 acquired AA patients who later developed hematologic malignancies. Data encompassed clinical, laboratory, karyotype, and next-generation sequencing (NGS) information. We explored chromosomal alterations and mutation profiles to uncover genetic changes underlying the transition...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38540708/senescence-promotes-the-recovery-of-stemness-among-cancer-cells-via-reprograming
#25
REVIEW
Di Wang, Lingbo Liu
Both the senescence of cancer cells and the maintenance of cancer stem cells seem to be mutually exclusive because senescence is considered a physiological mechanism that effectively suppresses tumor growth. Recent studies have revealed common signaling pathways between cellular senescence and the maintenance of stemness in cancer cells, thus challenging the conventional understanding of this process. Although the links between these processes have not yet been fully elucidated, emerging evidence indicates that senescent cancer cells can undergo reprograming to recover stemness...
February 28, 2024: Biomolecules
https://read.qxmd.com/read/38539418/venetoclax-plus-azacitidine-as-a-bridge-treatment-to-allogeneic-stem-cell-transplantation-in-unfit-patients-with-acute-myeloid-leukemia
#26
JOURNAL ARTICLE
Tzu-Ting Chen, Ching-Chan Lin, Wen-Jyi Lo, Ching-Yun Hsieh, Ming-Yu Lein, Che-Hung Lin, Chen-Yuan Lin, Li-Yuan Bai, Chang-Fang Chiu, Su-Peng Yeh
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) is rarely recommended for unfit patients with newly diagnosed acute myeloid leukemia (AML). Patient survival can improve with venetoclax plus azacitidine (VEN plus AZA). However, the long-term outcome of this treatment strategy is still unsatisfactory. The high response and low treatment toxicity rates of patients receiving VEN plus AZA can provide an opportunity for HSCT among unfit patients. Nevertheless, the outcomes and complications of VEN plus AZA, followed by HSCT, remain unclear...
March 7, 2024: Cancers
https://read.qxmd.com/read/38530315/exclusive-breastfeeding-duration-and-risk-of-childhood-cancers
#27
JOURNAL ARTICLE
Signe Holst Søegaard, Mie Mølgaard Andersen, Klaus Rostgaard, Olafur Birgir Davidsson, Sjurdur Frodi Olsen, Kjeld Schmiegelow, Henrik Hjalgrim
IMPORTANCE: Breastfeeding has been suggested to protect against childhood cancers, particularly acute lymphoblastic leukemia (ALL). However, the evidence stems from case-control studies alone. OBJECTIVE: To investigate whether longer duration of exclusive breastfeeding is associated with decreased risk of childhood ALL and other childhood cancers. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used administrative data on exclusive breastfeeding duration from the Danish National Child Health Register...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38517548/secondary-solid-malignancies-and-precancerous-lesions-after-allogeneic-hematopoietic-stem-cell-transplantation-using-non-total-body-irradiation-based-conditioning-in-acute-myeloid-leukemia
#28
JOURNAL ARTICLE
Gruber Isabella, Appel Katharina, Edinger Matthias, Koelbl Oliver, Wolff Daniel
INTRODUCTION: Long-term survivors have an increased risk of developing secondary solid malignancies (SSMs) after allogeneic-hematopoietic stem cell transplantation (allo-HSCT) with graft-versus-host disease (GVHD) potentially modulating these risks. METHODS: This retrospective study analyzed the cumulative incidences of SSMs after chemotherapy-based conditioning for allo-HSCT patients with acute myeloid leukemia (n = 266) transplanted at the University Hospital Regensburg between 1999 and 2016...
March 22, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38515317/the-relationship-between-hematologic-malignancies-on-male-hypogonadism-a-scoping-review
#29
JOURNAL ARTICLE
Bradley Roth, Muhammed A Moukhtar Hammad, Daniel I Sanford, Molly Piper, David W Barham, Faysal A Yafi, Lawrence C Jenkins
INTRODUCTION: The associated symptoms of hypogonadism have been reported in patients with various types of cancer. However, the prevalence and significance of hypogonadism among certain hematologic malignancies have not been completely summarized in recent literature. OBJECTIVE: In this review we aimed to examine the current literature on hypogonadism in patients with hematologic malignancies, with emphasis on leukemias, lymphomas, and multiple myeloma (MM). METHODS: This review included relevant studies published before July 2023 that were retrieved through a search of PubMed using the keywords "hematologic cancer," "hematologic malignancy," blood cancer," "leukemia," "lymphoma," "hypogonadism," "multiple myeloma," and "testosterone...
March 21, 2024: Sexual Medicine Reviews
https://read.qxmd.com/read/38510818/refractory-burkitt-lymphoma-diagnosis-and-interventional-strategies
#30
REVIEW
Francesco Malfona, Anna Maria Testi, Sabina Chiaretti, Maria Luisa Moleti
Despite excellent results in frontline therapy, particularly in pediatric age, refractory Burkitt lymphoma still remains a therapeutic challenge, with dismal outcome. The prognosis is very poor, ranging from less than 10% to 30-40%, with longer survival only in transplanted patients. On account of the paucity of data, mostly reporting on small series of patients, with heterogeneous characteristics and salvage treatments, at present it is impossible to draw definitive conclusions on the treatment of choice for this difficult to treat subset of patients...
2024: Blood and Lymphatic Cancer: Targets and Therapy
https://read.qxmd.com/read/38502829/azacitidine-combined-with-venetoclax-alleviates-aml-mr-with-tp53-mutation-in-sds-a-case-report-and-literature-review
#31
JOURNAL ARTICLE
Cuiping Ma, Haiyan Lang, Yuhan Chen, Lu Yang, Chong Wang, Lizhen Han, Xinyi Chen, Wei Ma
Shwachman-Diamond syndrome (SDS) is an autosomal recessive genetic disease, which is prone to transform into myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). TP53 mutation is a driving factor involved in the transformation of SDS into MDS/AML, and in the evolution of MDS to AML. Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is the only curable approach, however, challenge remains regarding the balance between efficacy and the high risk from treatment-related toxicity and mortality to achieve temporary disease control before transplantation to gain time and opportunities for transplantation...
March 15, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38502193/drug-regulated-cd33-targeted-car-t-cells-control-aml-using-clinically-optimized-rapamycin-dosing
#32
JOURNAL ARTICLE
Jacob Appelbaum, April E Price, Kaori Oda, Joy Zhang, Wai-Hang Leung, Giacomo Tampella, Dong Xia, Pauline Pl So, Sarah K Hilton, Claudya Evandy, Semanti Sarkar, Unja Martin, Anne-Rachel Krostag, Marissa Leonardi, Daniel E Zak, Rachael Logan, Paula Lewis, Secil Franke-Welch, Njabulo Ngwenyama, Michael Fitzgerald, Niklas Tulberg, Stephanie Rawlings-Rhea, Rebecca A Gardner, Kyle Jones, Angelica Sanabria, William Crago, John Timmer, Andrew Hollands, Brendan Eckelman, Sanela Bilic, Jim Woodworth, Adam Lamble, Philip D Gregory, Jordan Jarjour, Mark Pogson, Joshua A Gustafson, Alexander Astrakhan, Michael C Jensen
Chimeric antigen receptor (CAR) designs that incorporate pharmacologic control are desirable, however designs suitable for clinical translation are needed. We designed a fully human, rapamycin-regulated, drug product for targeting CD33+ tumors called dimerization agent regulated immunoreceptor complex (DARIC33). T cell products demonstrated target specific and rapamycin-dependent cytokine release, transcriptional responses, cytotoxicity, and in vivo antileukemic activity in the presence of as little as 1nM rapamycin...
March 19, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38500877/metabolic-instruction-of-the-graft-versus-leukemia-immunity
#33
REVIEW
Ann-Cathrin Burk, Petya Apostolova
Allogeneic hematopoietic cell transplantation (allo-HCT) is frequently performed to cure hematological malignancies, such as acute myeloid leukemia (AML), through the graft-versus-leukemia (GVL) effect. In this immunological process, donor immune cells eliminate residual cancer cells in the patient and exert tumor control through immunosurveillance. However, GVL failure and subsequent leukemia relapse are frequent and associated with a dismal prognosis. A better understanding of the mechanisms underlying AML immune evasion is essential for developing novel therapeutic strategies to boost the GVL effect...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38496369/burkitt-s-lymphoma-in-a-young-boy-progressing-to-systemic-lupus-erythematosus-during-follow-up-a-case-report-and-literature-review
#34
Chenxi Liu, Ci Pan, Yingying Jin, Hua Huang, Fei Ding, Xuemei Xu, Shengfang Bao, Xiqiong Han, Yanliang Jin
INTRODUCTION: Patients with systemic lupus erythematosus (SLE) are at a higher risk of developing cancer, particularly hematological malignancies such as lymphoma and leukemia. However, existing studies on this topic that assess cancer incidence following SLE diagnosis are limited. In addition, SLE can be diagnosed after cancer, although such cases in children have been rarely reported. CASE REPORT: We present the case of a 2.6-year-old boy who presented to our institute with fever and abdominal pain...
2024: Frontiers in Pediatrics
https://read.qxmd.com/read/38494064/bile-acids-serve-as-endogenous-antagonists-of-the-leukemia-inhibitory-factor-lif-receptor-in-oncogenesis
#35
JOURNAL ARTICLE
Cristina Di Giorgio, Elva Morretta, Antonio Lupia, Rachele Bellini, Carmen Massa, Ginevra Urbani, Martina Bordoni, Silvia Marchianò, Ginevra Lachi, Pasquale Rapacciuolo, Claudia Finamore, Valentina Sepe, Maria Chiara Monti, Federica Moraca, Nicola Natalizi, Luigina Graziosi, Eleonora Distrutti, Michele Biagioli, Bruno Catalanotti, Annibale Donini, Angela Zampella, Stefano Fiorucci
The leukemia inhibitory factor (LIF) is member of interleukin (IL)-6 family of cytokines involved immune regulation, morphogenesis and oncogenesis. In cancer tissues, LIF binds a heterodimeric receptor (LIFR), formed by a LIFRβ subunit and glycoprotein(gp)130, promoting epithelial mesenchymal transition and cell growth. Bile acids are cholesterol metabolites generated at the interface of host metabolism and the intestinal microbiota. Here we demonstrated that bile acids serve as endogenous antagonist to LIFR in oncogenesis...
March 15, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38493578/rare-nup98-prrx1-fusion-transcript-in-a-therapy-related-acute-myeloid-leukemia-associated-with-del-7q-following-chemotherapy-for-diffuse-large-b-cell-lymphoma
#36
JOURNAL ARTICLE
Yanfang Wang, Zhenhao Zhang, Lingli Wang, Hua Wang, Fei Dong
BACKGROUND: Therapy-related acute myeloid leukemia (t-AML) is increasingly recognized as a treatment complication in patients receiving chemotherapy, radiotherapy, or immunosuppressive agents for primary neoplasms. NUP98::PRRX1 fusion gene, caused by t(1;11)(q23;p15), is a rare recurrent cytogenetic alteration in leukemia, and only seven cases with NUP98::PRRX1 were reported so far. METHODS: A 53-year-old female patient was diagnosed with t-AML after 20 months of complete remission (CR) from diffuse large B-cell lymphoma (DLBCL)...
March 12, 2024: Cancer Genetics
https://read.qxmd.com/read/38492861/sting-activating-cyclic-dinucleotide-manganese-nanoparticles-evoke-robust-immunity-against-acute-myeloid-leukemia
#37
JOURNAL ARTICLE
Marisa E Aikins, Xiaoqi Sun, Hannah Dobson, Xingwu Zhou, Yao Xu, Yu Leo Lei, James J Moon
Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults with a 5-year survival rate of 30.5%. These poor patient outcomes are attributed to tumor relapse, stemming from ineffective innate immune activation, T cell tolerance, and a lack of immunological memory. Thus, new strategies are needed to activate innate and effector immune cells and evoke long-term immunity against AML. One approach to address these issues is through Stimulator of Interferon Genes (STING) pathway activation, which produces Type I Interferons (Type I IFN) critical for innate and adaptive immune activation...
March 20, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38490099/cancer-stem-cells-the-important-role-of-cd-markers-signaling-pathways-and-micrornas
#38
REVIEW
Amir Gholamzad, Niloofar Khakpour, Elaheh Mohandesi Khosroshahi, Saba Asadi, Zeinab Khazaei Koohpar, Arash Matinahmadi, Ali Jebali, Mohsen Rashidi, Mehrdad Hashemi, Farzaneh Hasani Sadi, Mehrdad Gholamzad
For the first time, a subset of small cancer cells identified in acute myeloid leukemia has been termed Cancer Stem Cells (CSCs). These cells are notorious for their robust proliferation, self-renewal abilities, significant tumor-forming potential, spread, and resistance to treatments. CSCs are a global concern, as it found in numerous types of cancer, posing a real-world challenge today. Our review encompasses research on key CSC markers, signaling pathways, and MicroRNA in three types of cancer: breast, colon, and liver...
February 28, 2024: Pathology, Research and Practice
https://read.qxmd.com/read/38486826/a-nursing-pre-transplant-intervention-to-reduce-patients-uncertainty-about-allogeneic-hematopoietic-stem-cell-transplantation
#39
JOURNAL ARTICLE
Kimiko Nakano, Shiro Fujii, Ayame Fujioka, Kumi Kimura, Yoshiki Abe, Masahiro Abe, Sena Yamamoto, Harue Arao
Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) procedures often experience high levels of uncertainty. In this study, we developed and implemented a nursing intervention program to help patients recognize and reduce pre-transplant uncertainty. This study used a pretest-posttest single-group design without a control group. Eighteen patients undergoing HSCT participated in the intervention program-which included informational support, confirmation that the patients understood the information provided, and emotional support...
February 25, 2024: Blood Cell Ther
https://read.qxmd.com/read/38481552/curcumin-in-treatment-of-hematological-cancers-promises-and-challenges
#40
REVIEW
Maliheh Entezari, Armita Tayari, Mahshid Deldar Abad Paskeh, Simin Khorsand Kheirabad, Sahar Naeemi, Afshin Taheriazam, Hossein Dehghani, Shokooh Salimimoghadam, Mehrdad Hashemi, Sepideh Mirzaei, Saeed Samarghandian
Hematological cancers include leukemia, myeloma and lymphoma and up to 178.000 new cases are diagnosed with these tumors each year. Different kinds of treatment including radiotherapy, chemotherapy, immunotherapy and stem cell transplantation have been employed in the therapy of hematological cancers. However, they are still causing death among patients. On the other hand, curcumin as an anti-cancer agent for the suppression of human cancers has been introduced. The treatment of hematological cancers using curcumin has been followed...
March 2024: Journal of Traditional and Complementary Medicine
keyword
keyword
61035
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.